'I do deserve care': AG report on out-of-province health care is validating, says patient - CBC

IntroductionWe understand digital health solutions (DHS) as “information and communications technologies in medicine […] to manage illnesses and health risks and to promote wellness”1. DHS are widely considered to hold substantial potential for transforming health care delivery. Prior research has shown that DHS can improve clinical outcomes2, but also non-clinical aspects of health care delivery, such as the overall patient experience and service quality. For instance, DHS have been shown to enhance accessibility3, improve organizational processes4, and reduce costs5,6. Despite these advantages and a rapidly growing availability of DHS7, adoption in outpatient care remains comparatively slow. This is partly due to the structure of outpatient care with its typically smaller practices and limited organizational resources, for instance no dedicated IT or procurement units8,9. A central barrier to DHS adoption is the comparison of the efforts and costs for the implementation and maintenance against the effects of DHS10,11, which is a central consideration for practice owners and managers to select DHS for their practices as well as for payers and policymakers assessing DHS strategies.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.